BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22242671)

  • 1. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.
    Chiba Y; Kinoshita M; Okita Y; Tsuboi A; Isohashi K; Kagawa N; Fujimoto Y; Oji Y; Oka Y; Shimosegawa E; Morita S; Hatazawa J; Sugiyama H; Hashimoto N; Yoshimine T
    J Neurosurg; 2012 Apr; 116(4):835-42. PubMed ID: 22242671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
    Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
    J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-tumor histogram analysis of the cerebral blood volume map: tumor volume defined by 11C-methionine positron emission tomography image improves the diagnostic accuracy of cerebral glioma grading.
    Wu R; Watanabe Y; Arisawa A; Takahashi H; Tanaka H; Fujimoto Y; Watabe T; Isohashi K; Hatazawa J; Tomiyama N
    Jpn J Radiol; 2017 Oct; 35(10):613-621. PubMed ID: 28879406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy.
    Grosu AL; Weber WA; Riedel E; Jeremic B; Nieder C; Franz M; Gumprecht H; Jaeger R; Schwaiger M; Molls M
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):64-74. PubMed ID: 16111573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.
    Harris RJ; Cloughesy TF; Pope WB; Nghiemphu PL; Lai A; Zaw T; Czernin J; Phelps ME; Chen W; Ellingson BM
    Neuro Oncol; 2012 Aug; 14(8):1079-89. PubMed ID: 22711609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.
    Ideguchi M; Nishizaki T; Ikeda N; Okamura T; Tanaka Y; Fujii N; Ohno M; Shimabukuro T; Kimura T; Ikeda E; Suga K
    J Neurooncol; 2018 Jul; 138(3):537-548. PubMed ID: 29516344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.
    Roessler K; Gatterbauer B; Becherer A; Paul M; Kletter K; Prayer D; Hoeftberger R; Hainfellner J; Asenbaum S; Knosp E
    Minim Invasive Neurosurg; 2007 Oct; 50(5):273-80. PubMed ID: 18058643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma.
    Tsuyuguchi N; Takami T; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Nishikawa M; Ohata K; Torii K; Morino M; Nishio A; Hara M
    Ann Nucl Med; 2004 Jun; 18(4):291-6. PubMed ID: 15359921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of post-treatment metabolic tumor volume from
    Jung TY; Min JJ; Bom HS; Jung S; Kim IY; Lim SH; Kim DY; Kwon SY
    Neurosurg Rev; 2017 Apr; 40(2):223-229. PubMed ID: 27282449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas].
    Yamaguchi S; Terasaka S; Kobayashi H; Narita T; Hirata K; Shiga S; Usui R; Tanaka S; Kubota K; Murata J; Asaoka K
    No Shinkei Geka; 2010 Jul; 38(7):621-8. PubMed ID: 20628188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging.
    Tietze A; Boldsen JK; Mouridsen K; Ribe L; Dyve S; Cortnum S; Østergaard L; Borghammer P
    Acta Radiol; 2015 Sep; 56(9):1135-44. PubMed ID: 25270372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging of non- or very subtle contrast-enhancing malignant gliomas with [¹¹C]-methionine positron emission tomography.
    Galldiks N; Kracht LW; Dunkl V; Ullrich RT; Vollmar S; Jacobs AH; Fink GR; Schroeter M
    Mol Imaging; 2011 Dec; 10(6):453-9. PubMed ID: 22201536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioma grading by dynamic susceptibility contrast perfusion and
    Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Reischl G; Bender B; Ernemann U; la Fougère C; Klose U
    Neuroradiology; 2018 Apr; 60(4):381-389. PubMed ID: 29464269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
    Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
    Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sequential analysis of the integrated images of PET, CT and MR in malignant brain tumors before and after radiotherapy].
    Suzuki A; Mineura K; Sasajima T; Kowada M; Ogawa T; Hatazawa J; Uemura K
    No To Shinkei; 1996 May; 48(5):449-57. PubMed ID: 8672304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.
    Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T
    Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
    Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
    Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal changes in diffusivity on apparent diffusion coefficient MR imaging and amino acid uptake on PET do not colocalize in nonenhancing low-grade gliomas.
    Rahm V; Boxheimer L; Bruehlmeier M; Berberat J; Nitzsche EU; Remonda L; Roelcke U
    J Nucl Med; 2014 Apr; 55(4):546-50. PubMed ID: 24566001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.